Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy
Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy
About this item
Full title
Author / Creator
Publisher
New Zealand: Taylor & Francis Ltd
Journal title
Language
English
Formats
Publication information
Publisher
New Zealand: Taylor & Francis Ltd
Subjects
More information
Scope and Contents
Contents
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a progressive neurodegenerative disease that results in early-onset, severe, progressive, neurological disabilities, leading to death in late childhood or early adolescence. Management has relied on symptomatic care, and supportive and palliative strategies, but the approval of the enzyme repl...
Alternative Titles
Full title
Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7127909
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7127909
Other Identifiers
ISSN
1178-203X,1176-6336
E-ISSN
1178-203X
DOI
10.2147/TCRM.S241048
